4,4-dimethyl-1-[4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione | 87789-64-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4,4-dimethyl-1-[4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione
• 英文别名: 1-{4-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-butyl}-4,4-dimethyl-piperidine-2,6-dione；1-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butyl]-4,4-dimethylpiperidine-2,6-dione
• CAS: 87789-64-8
• 化学式: C₁₉H₂₈FN₅O₂
• 分子量: 377.462
• InChiKey: LQZNZOFFHWVJSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-氟-2-(1-哌嗪基)-嘧啶 、 1-(4-溴丁基)-4,4-二甲基哌啶-2,6-二酮 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4,4-dimethyl-1-[4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione
  参考文献：
  名称：

  The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands

  摘要：

  New arylpiperazines related to buspirone, gepirone and NAN-190 were designed and screened in silico for their 5-HT1A affinity and potential sites of metabolism by human cytochrome P450 (CYP3A4). Modifications to these structures were assessed in silico for their influence on both 5HT(1A) affinity and metabolism. Selected new molecules were synthesized and purified in a parallel chemistry approach to determine structure activity relationships (SARs). The resulting molecules were assessed in vitro for their 5HT(1A) affinity and half-life in a heterologously expressed human CYP3A4 assay. Molecular features responsible for 5-HT1A affinity and CYP3A4 stability are described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.045

文献信息

• 5 HT RECEPTOR MEDIATED NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20100009983A1

  公开（公告）日：2010-01-14

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.
• The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands
  作者：Manish Tandon、Mary-Margaret O'Donnell、Alex Porte、David Vensel、Donglai Yang、Rocio Palma、Alan Beresford、Mark A. Ashwell

  DOI：10.1016/j.bmcl.2004.01.045

  日期：2004.4

  New arylpiperazines related to buspirone, gepirone and NAN-190 were designed and screened in silico for their 5-HT1A affinity and potential sites of metabolism by human cytochrome P450 (CYP3A4). Modifications to these structures were assessed in silico for their influence on both 5HT(1A) affinity and metabolism. Selected new molecules were synthesized and purified in a parallel chemistry approach to determine structure activity relationships (SARs). The resulting molecules were assessed in vitro for their 5HT(1A) affinity and half-life in a heterologously expressed human CYP3A4 assay. Molecular features responsible for 5-HT1A affinity and CYP3A4 stability are described. (C) 2004 Elsevier Ltd. All rights reserved.